$8.15 -0.34 (-4.01%) OncoMed Pharmaceuticals Inc - NASDAQ

Dec. 7, 2016 | 04:00 PM

Quotes

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Last Trade: 8.15
Trade Time: Dec 07 04:00 PM Eastern Daylight Time
Change: -0.34 (-4.01%)
Prev Close: 8.49
Open: 8.34
Bid: 8.16
Ask: 8.17
  1. No results found.
  1. Bristol-Myers Falls As Merck Upstages With New Lung Cancer Data

    TalkMarkets | Oct. 10, 2016 | 18:35PM EST
  2. Celgene, Vertex, Illumina Offer Mixed Outlooks

    IBD | Jan. 11, 2016 | 19:05PM EST
  3. Celgene Numbers Disappoint; New CEO Announced

    IBD | Jan. 11, 2016 | 13:59PM EST
  4. Benzinga's Volume Movers

    Benzinga | Dec. 24, 2015 | 10:33AM EST
  5. OncoMed Presents Positive Immuno-Oncology Data for Combined Blockade of DLL4, VEGF and PD1 at SITC Conference

    Benzinga | Nov. 7, 2015 | 17:23PM EST
  6. OncoMed Reports Presentation of Phase 1b Trial for Tarextumab in Small Cell Lung Cancer at ASCO

    Benzinga | Jun. 1, 2015 | 08:09AM EST
  7. Oncomed Offers Data from Phase 1a Trial of OMP-52M51 in Oral Plenary Session

    Benzinga | Nov. 19, 2014 | 07:53AM EST
  8. 3 Companies Investing In Stem Cell Research

    Benzinga | Sep. 14, 2014 | 15:34PM EST
  9. Events for the Week of Sept. 8-12

    Benzinga | Sep. 10, 2014 | 13:34PM EST
  10. Mid-Afternoon Market Update: Markets Reverse Early Loses; Oil Continues To Rise On Overseas Worry

    Benzinga | Jun. 13, 2014 | 14:36PM EST
  11. Mid-Morning Market Update: Markets Mostly Flat; Priceline To Acquire OpenTable For $103/Share

    Benzinga | Jun. 13, 2014 | 09:25AM EST
  12. Morning Market Losers

    Benzinga | Jun. 13, 2014 | 08:44AM EST
  13. OncoMed Presents Data on Multiple Anti-Cancer Stem Cell Programs at American Association for Cancer Research Annual Meeting

    Benzinga | Apr. 8, 2014 | 07:39AM EST
  14. OncoMed Pharmaceuticals Commences Third Phase 1b Clinical Trial for OMP-54F28 (Fzd8-Fc) With Carboplatin and Paclitaxel in Ovarian Cancer

    Benzinga | Feb. 20, 2014 | 08:33AM EST
  15. UPDATE: OncoMed Pharmaceuticals Initiates Second Phase 1b Clinical Trial for OMP-54F28 (Fzd8-Fc) With Sorafenib (Nexavar(R)) in Hepatocellular Cancer

    Benzinga | Feb. 18, 2014 | 08:30AM EST
Trading Center